Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 603

1.

Are there gender disparities in symptom presentation or triage of patients with chest discomfort at primary care out-of-hours services? An observational study.

van der Meer MG, Appelman Y, Rutten KHG, van der Graaf Y, Nathoe HM, Doevendans PA, Smit M, Verheij E, Botermans A, Rutten FH.

BMJ Open. 2019 Nov 19;9(11):e031613. doi: 10.1136/bmjopen-2019-031613.

2.

Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes.

de Vries TI, de Valk HW, van der Graaf Y, de Borst GJ, Cramer MJM, Jaap Kappelle L, Visseren FLJ, Westerink J; SMART study group.

Diabetes Res Clin Pract. 2019 Nov;157:107880. doi: 10.1016/j.diabres.2019.107880. Epub 2019 Oct 16.

PMID:
31628967
3.

The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study.

Van't Klooster CC, Ridker PM, Hjortnaes J, van der Graaf Y, Asselbergs FW, Westerink J, Aerts JGJV, Visseren FLJ.

Eur Heart J. 2019 Dec 21;40(48):3901-3909. doi: 10.1093/eurheartj/ehz587.

4.

Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.

de Vries TI, Eikelboom JW, Bosch J, Westerink J, Dorresteijn JAN, Alings M, Dyal L, Berkowitz SD, van der Graaf Y, Fox KAA, Visseren FLJ.

Eur Heart J. 2019 Dec 7;40(46):3771-3778a. doi: 10.1093/eurheartj/ehz404.

PMID:
31504399
5.

Subjective cognitive decline, brain imaging biomarkers, and cognitive functioning in patients with a history of vascular disease: the SMART-Medea study.

Blom K, Koek HL, Zwartbol MHT, van der Graaf Y, Kesseler L, Biessels GJ, Geerlings MI; SMART Study Group.

Neurobiol Aging. 2019 Dec;84:33-40. doi: 10.1016/j.neurobiolaging.2019.07.011. Epub 2019 Jul 24.

6.

Heterogeneity of Treatment Effects From an Intensive Lifestyle Weight Loss Intervention on Cardiovascular Events in Patients With Type 2 Diabetes: Data From the Look AHEAD Trial.

de Vries TI, Dorresteijn JAN, van der Graaf Y, Visseren FLJ, Westerink J.

Diabetes Care. 2019 Oct;42(10):1988-1994. doi: 10.2337/dc19-0776. Epub 2019 Aug 15.

PMID:
31416897
7.

Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease.

van den Berg MJ, van der Graaf Y, Deckers JW, de Kanter W, Algra A, Kappelle LJ, de Borst GJ, Cramer MM, Visseren FLJ; SMART study group.

Am Heart J. 2019 Jul;213:112-122. doi: 10.1016/j.ahj.2019.03.019. Epub 2019 Apr 25.

8.

Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people.

Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, Geisel MH, Lehmann N, Erbel R, Jöckel KH, van der Graaf Y, Verschuren WMM, Boer JMA, Nambi V, Visseren FLJ, Dorresteijn JAN.

Eur Heart J. 2019 May 18. pii: ehz239. doi: 10.1093/eurheartj/ehz239. [Epub ahead of print]

PMID:
31102402
9.

Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: Findings from the SMART cohort.

Sharif S, Groenwold RHH, van der Graaf Y, Berkelmans GFN, Cramer MJ, Visseren FLJ, Westerink J; SMART study group.

Diabetes Obes Metab. 2019 Aug;21(8):1935-1943. doi: 10.1111/dom.13759. Epub 2019 May 23.

10.

Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.

Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ.

Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.

PMID:
31046423
11.

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.

Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J; CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002471. doi: 10.1161/CIRCGEN.119.002471. Epub 2019 Mar 21.

PMID:
30897348
12.

Subsequent Event Risk in Individuals With Established Coronary Heart Disease.

Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrøm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002470. doi: 10.1161/CIRCGEN.119.002470. Epub 2019 Mar 21.

PMID:
30896328
13.

Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting.

Chauhan G, Adams HHH, Satizabal CL, Bis JC, Teumer A, Sargurupremraj M, Hofer E, Trompet S, Hilal S, Smith AV, Jian X, Malik R, Traylor M, Pulit SL, Amouyel P, Mazoyer B, Zhu YC, Kaffashian S, Schilling S, Beecham GW, Montine TJ, Schellenberg GD, Kjartansson O, Guðnason V, Knopman DS, Griswold ME, Windham BG, Gottesman RF, Mosley TH, Schmidt R, Saba Y, Schmidt H, Takeuchi F, Yamaguchi S, Nabika T, Kato N, Rajan KB, Aggarwal NT, De Jager PL, Evans DA, Psaty BM, Rotter JI, Rice K, Lopez OL, Liao J, Chen C, Cheng CY, Wong TY, Ikram MK, van der Lee SJ, Amin N, Chouraki V, DeStefano AL, Aparicio HJ, Romero JR, Maillard P, DeCarli C, Wardlaw JM, Hernández MDCV, Luciano M, Liewald D, Deary IJ, Starr JM, Bastin ME, Muñoz Maniega S, Slagboom PE, Beekman M, Deelen J, Uh HW, Lemmens R, Brodaty H, Wright MJ, Ames D, Boncoraglio GB, Hopewell JC, Beecham AH, Blanton SH, Wright CB, Sacco RL, Wen W, Thalamuthu A, Armstrong NJ, Chong E, Schofield PR, Kwok JB, van der Grond J, Stott DJ, Ford I, Jukema JW, Vernooij MW, Hofman A, Uitterlinden AG, van der Lugt A, Wittfeld K, Grabe HJ, Hosten N, von Sarnowski B, Völker U, Levi C, Jimenez-Conde J, Sharma P, Sudlow CLM, Rosand J, Woo D, Cole JW, Meschia JF, Slowik A, Thijs V, Lindgren A, Melander O, Grewal RP, Rundek T, Rexrode K, Rothwell PM, Arnett DK, Jern C, Johnson JA, Benavente OR, Wasssertheil-Smoller S, Lee JM, Wong Q, Mitchell BD, Rich SS, McArdle PF, Geerlings MI, van der Graaf Y, de Bakker PIW, Asselbergs FW, Srikanth V, Thomson R, McWhirter R, Moran C, Callisaya M, Phan T, Rutten-Jacobs LCA, Bevan S, Tzourio C, Mather KA, Sachdev PS, van Duijn CM, Worrall BB, Dichgans M, Kittner SJ, Markus HS, Ikram MA, Fornage M, Launer LJ, Seshadri S, Longstreth WT Jr, Debette S; Stroke Genetics Network (SiGN), the International Stroke Genetics Consortium (ISGC), METASTROKE, Alzheimer's Disease Genetics Consortium (ADGC), and the Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium.

Neurology. 2019 Jan 16. pii: 10.1212/WNL.0000000000006851. doi: 10.1212/WNL.0000000000006851. [Epub ahead of print]

14.

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.

Berkelmans GFN, Gudbjörnsdottir S, Visseren FLJ, Wild SH, Franzen S, Chalmers J, Davis BR, Poulter NR, Spijkerman AM, Woodward M, Pressel SL, Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH, Eliasson B, Dorresteijn JAN.

Eur Heart J. 2019 Sep 7;40(34):2899-2906. doi: 10.1093/eurheartj/ehy839.

PMID:
30629157
15.

[What are the benefits of MRI scans for people without symptoms?]

van der Graaf Y, van Eijsden P.

Ned Tijdschr Geneeskd. 2018 Dec 18;162. pii: D3695. Dutch.

PMID:
30604600
16.

Intracranial Vessel Wall Lesions on 7T MRI (Magnetic Resonance Imaging).

Zwartbol MHT, van der Kolk AG, Ghaznawi R, van der Graaf Y, Hendrikse J, Geerlings MI; SMART Study Group.

Stroke. 2019 Jan;50(1):88-94. doi: 10.1161/STROKEAHA.118.022509.

PMID:
30582831
17.

MRI phenotypes of the brain are related to future stroke and mortality in patients with manifest arterial disease: The SMART-MR study.

Jaarsma-Coes MG, Ghaznawi R, Hendrikse J, Slump C, Witkamp TD, van der Graaf Y, Geerlings MI, de Bresser J; Second Manifestations of ARTerial disease (SMART) Study group.

J Cereb Blood Flow Metab. 2020 Feb;40(2):354-364. doi: 10.1177/0271678X18818918. Epub 2018 Dec 14.

18.

Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model.

Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D'Agostino RB Sr, Massaro JM, van der Graaf Y, Cramer MJM, Kappelle LJ, de Borst GJ, Steg PG, Visseren FLJ.

J Am Heart Assoc. 2018 Aug 21;7(16):e009217. doi: 10.1161/JAHA.118.009217.

19.

Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus.

de Vries TI, Kappelle LJ, van der Graaf Y, de Valk HW, de Borst GJ, Nathoe HM, Visseren FLJ, Westerink J; SMART study group.

Acta Diabetol. 2019 Apr;56(4):431-440. doi: 10.1007/s00592-018-1231-y. Epub 2018 Sep 27.

20.

The association between lacunes and white matter hyperintensity features on MRI: The SMART-MR study.

Ghaznawi R, Geerlings MI, Jaarsma-Coes MG, Zwartbol MH, Kuijf HJ, van der Graaf Y, Witkamp TD, Hendrikse J, de Bresser J.

J Cereb Blood Flow Metab. 2019 Dec;39(12):2486-2496. doi: 10.1177/0271678X18800463. Epub 2018 Sep 11.

21.

The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease.

Schrover IM, van der Graaf Y, Spiering W, Visseren FL; SMART study group.

Eur J Prev Cardiol. 2018 Sep;25(14):1548-1557. doi: 10.1177/2047487318790722. Epub 2018 Jul 27.

22.

Combined use of polypill components in patients with type 2 diabetes mellitus.

Janssen VE, Visseren FL, de Boer A, Grobbee DE, Westerink J, van der Graaf Y, Lafeber M; SMART Study Group.

Eur J Prev Cardiol. 2018 Sep;25(14):1523-1531. doi: 10.1177/2047487318789494. Epub 2018 Jul 23.

PMID:
30033753
23.

Hippocampal sulcal cavities: prevalence, risk factors and association with cognitive performance. The SMART-Medea study and PREDICT-MR study.

Blom K, Koek HL, van der Graaf Y, Zwartbol MHT, Wisse LEM, Hendrikse J, Biessels GJ, Geerlings MI; SMART Study Group.

Brain Imaging Behav. 2019 Aug;13(4):1093-1102. doi: 10.1007/s11682-018-9916-y.

24.

Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.

van Kleef MEAM, Visseren FLJ, Vernooij JWP, Nathoe HM, Cramer MM, Bemelmans RHH, van der Graaf Y, Spiering W; SMART-study group.

J Hypertens. 2018 Sep;36(9):1865-1873. doi: 10.1097/HJH.0000000000001785.

PMID:
29878973
25.

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives.

Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, Dorresteijn JAN.

BMJ Open. 2018 May 26;8(5):e021309. doi: 10.1136/bmjopen-2017-021309.

26.

Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes.

Hanssen NMJ, Westerink J, Scheijen JLJM, van der Graaf Y, Stehouwer CDA, Schalkwijk CG; SMART Study Group.

Diabetes Care. 2018 Aug;41(8):1689-1695. doi: 10.2337/dc18-0159. Epub 2018 May 21.

PMID:
29784769
27.

Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients.

Østergaard HB, Mandrup-Poulsen T, Berkelmans GFN, van der Graaf Y, Visseren FLJ, Westerink J; SMART Study Group.

Diabetes Metab. 2019 Jun;45(3):254-260. doi: 10.1016/j.diabet.2018.04.006. Epub 2018 May 8.

PMID:
29784563
28.

Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.

Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ.

Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.

29.

Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes.

Koopal C, Visseren FLJ, Westerink J, van der Graaf Y, Ginsberg HN, Keech AC.

Diabetes Care. 2018 Jun;41(6):1244-1250. doi: 10.2337/dc17-0968. Epub 2018 Feb 22.

PMID:
29472432
30.

Prevalence of Subclinical Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography in 45- to 55-Year-Old Women With a History of Preeclampsia.

Zoet GA, Benschop L, Boersma E, Budde RPJ, Fauser BCJM, van der Graaf Y, de Groot CJM, Maas AHEM, Roeters van Lennep JE, Steegers EAP, Visseren FL, van Rijn BB, Velthuis BK, Franx A; CREW Consortium.

Circulation. 2018 Feb 20;137(8):877-879. doi: 10.1161/CIRCULATIONAHA.117.032695. No abstract available.

PMID:
29459475
31.

Computed Tomography Perfusion Derived Blood-Brain Barrier Permeability Does Not Yet Improve Prediction of Hemorrhagic Transformation.

Horsch AD, Bennink E, van Seeters T, Kappelle LJ, van der Graaf Y, Mali WPTM, de Jong HWAM, Velthuis BK, Dankbaar JW; DUST Investigators.

Cerebrovasc Dis. 2018;45(1-2):26-32. doi: 10.1159/000485043. Epub 2018 Jan 8.

32.

Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.

Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ.

Int J Cardiol. 2018 Feb 15;253:148-154. doi: 10.1016/j.ijcard.2017.10.080.

PMID:
29306457
33.

Validation of an imaging based cardiovascular risk score in a Scottish population.

Kockelkoren R, Jairam PM, Murchison JT, Debray TPA, Mirsadraee S, van der Graaf Y, Jong PA, van Beek EJR.

Eur J Radiol. 2018 Jan;98:143-149. doi: 10.1016/j.ejrad.2017.11.016. Epub 2017 Nov 23.

34.

Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.

Harrison SC, Holmes MV, Burgess S, Asselbergs FW, Jones GT, Baas AF, van 't Hof FN, de Bakker PIW, Blankensteijn JD, Powell JT, Saratzis A, de Borst GJ, Swerdlow DI, van der Graaf Y, van Rij AM, Carey DJ, Elmore JR, Tromp G, Kuivaniemi H, Sayers RD, Samani NJ, Bown MJ, Humphries SE.

JAMA Cardiol. 2018 Jan 1;3(1):26-33. doi: 10.1001/jamacardio.2017.4293. Review. Erratum in: JAMA Cardiol. 2018 Jan 1;3(1):90.

35.

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.

de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J.

Cardiovasc Diabetol. 2017 Oct 16;16(1):134. doi: 10.1186/s12933-017-0617-4. Review.

36.

Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Koopal C, Marais AD, Westerink J, van der Graaf Y, Visseren FLJ.

J Lipid Res. 2017 Nov;58(11):2180-2187. doi: 10.1194/jlr.M076901. Epub 2017 Sep 19.

37.

Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes.

Engelen SE, van der Graaf Y, Stam-Slob MC, Grobbee DE, Cramer MJ, Kappelle LJ, de Borst GJ, Visseren FLJ, Westerink J; SMART study group.

Int J Cardiol. 2017 Dec 1;248:301-307. doi: 10.1016/j.ijcard.2017.07.081. Epub 2017 Jul 23.

PMID:
28802735
38.

Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease.

Jaspers NEM, Dorresteijn JAN, van der Graaf Y, Westerink J, Kappelle LJ, Nathoe HM, Algra A, Visseren FLJ.

Int J Obes (Lond). 2017 Dec;41(12):1775-1781. doi: 10.1038/ijo.2017.184. Epub 2017 Aug 4.

PMID:
28775374
39.

SPRINT trial: It's not just the blood pressure!

Berkelmans GF, Visseren FL, Jaspers NE, Spiering W, van der Graaf Y, Dorresteijn JA.

Eur J Prev Cardiol. 2017 Sep;24(14):1482-1484. doi: 10.1177/2047487317723213. Epub 2017 Jul 27.

PMID:
28749177
40.

Physical Activity and Characteristics of the Carotid Artery Wall in High-Risk Patients-The SMART (Second Manifestations of Arterial Disease) Study.

Boss HM, van der Graaf Y, Visseren FLJ, Van den Berg-Vos RM, Bots ML, de Borst GJ, Cramer MJ, Kappelle LJ, Geerlings MI; SMART Study Group.

J Am Heart Assoc. 2017 Jul 23;6(7). pii: e005143. doi: 10.1161/JAHA.116.005143.

41.

Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis.

Berkelmans GFN, van der Graaf Y, Dorresteijn JAN, de Borst GJ, Cramer MJ, Kappelle LJ, Westerink J, Visseren FLJ; SMART study group.

Int J Cardiol. 2018 Jan 15;251:96-102. doi: 10.1016/j.ijcard.2017.07.026. Epub 2017 Jul 14.

42.

Risk Factors for Recurrent Cardiovascular Events Before Age 65 Years or Within 2.5 Years of a Recent First Cardiovascular Event.

van den Berg MJ, Westerink J, van der Graaf Y, Kappelle LJ, de Borst GJ, Cramer MM, Visseren FLJ; SMART study group.

Am J Cardiol. 2017 Jul 15;120(2):167-173. doi: 10.1016/j.amjcard.2017.04.002. Epub 2017 Apr 27.

PMID:
28532782
43.

Relation between Kidney Length and Cardiovascular and Renal Risk in High-Risk Patients.

van der Sande NGC, Visseren FLJ, van der Graaf Y, Nathoe HM, de Borst GJ, Leiner T, Blankestijn PJ; SMART Study Group.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):921-928. doi: 10.2215/CJN.08990816. Epub 2017 May 9.

44.

Detection and characterization of small infarcts in the caudate nucleus on 7 Tesla MRI: The SMART-MR study.

Ghaznawi R, de Bresser J, van der Graaf Y, Zwartbol MH, Witkamp TD, Geerlings MI, Hendrikse J; SMART Study Group *.

J Cereb Blood Flow Metab. 2018 Sep;38(9):1609-1617. doi: 10.1177/0271678X17705974. Epub 2017 Apr 24.

45.

Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.

van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FLJ; SMART study group; REACH Registry investigators.

Eur Heart J. 2017 Nov 14;38(43):3211-3218. doi: 10.1093/eurheartj/ehx102.

PMID:
28369481
46.

Response by Kaasenbrood et al to Letter Regarding Article, "Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population".

Kaasenbrood L, van der Graaf Y, Visseren FL.

Circulation. 2017 Mar 28;135(13):e820-e821. doi: 10.1161/CIRCULATIONAHA.117.027317. No abstract available.

PMID:
28348097
47.

Relation of Epicardial Adipose Tissue Radiodensity to Coronary Artery Calcium on Cardiac Computed Tomography in Patients at High Risk for Cardiovascular Disease.

Franssens BT, Nathoe HM, Visseren FL, van der Graaf Y, Leiner T; SMART Study Group.

Am J Cardiol. 2017 May 1;119(9):1359-1365. doi: 10.1016/j.amjcard.2017.01.031. Epub 2017 Feb 11.

PMID:
28279438
48.

Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.

Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL.

J Am Heart Assoc. 2017 Feb 18;6(2). pii: e004648. doi: 10.1161/JAHA.116.004648.

49.

Do Lacunar Infarcts Have Different Aetiologies? Risk Factor Profiles of Lacunar Infarcts in Deep White Matter and Basal Ganglia: The Second Manifestations of ARTerial Disease-Magnetic Resonance Study.

Kloppenborg RP, Nederkoorn PJ, Grool AM, De Cocker LJ, Mali WP, van der Graaf Y, Geerlings MI; SMART Study Group.

Cerebrovasc Dis. 2017;43(3-4):161-168. doi: 10.1159/000454782. Epub 2017 Jan 31.

50.

Relation between brown adipose tissue and measures of obesity and metabolic dysfunction in patients with cardiovascular disease.

Franssens BT, Hoogduin H, Leiner T, van der Graaf Y, Visseren FLJ.

J Magn Reson Imaging. 2017 Aug;46(2):497-504. doi: 10.1002/jmri.25594. Epub 2017 Jan 27.

PMID:
28130811

Supplemental Content

Loading ...
Support Center